Lotemax is used in dry eye syndrome to decrease and eliminate inflammation of the ocular surface caused by the hyperosmolarity of the tears. The inflammation must first be brought under control before any other treatments can be optimally effective. Lotemax would typically be prescribed for two weeks to three months initially and then may need to be used again on a 1-2 week regimen periodically if the inflammation occurs again. Lotemax ointment has become a choice of many doctors to treat inflammation caused by dry eye (ocular surface disease) because it can be used at night with a long contact period to the eye's surfaces and provide some functional lubrication while the eyes are closed.
Steroid and antibiotic eye drops - hydrocortisone/neomycin/polymixin B; loteprednol/tobramycin; prednisolone/gentamycin; prednisolone/sulfacetamide; hydrocortisone /neomycin/bacitracin/ polymyxin B (Blephamide, Catapred [discontinued], Isopto, Pred-G, Poly-Pred [discontinued], Tobradex, Zylet and many other brands) are steroid and antibiotic eye drops prescribed to prevent or treat eye infections that are associated with inflammation. Side effects, drug interactions, dosage, and pregnancy safety information should be reviewed prior to using these medications.
Results from oral and ocular administration of Lotemax in normal volunteers have shown that there are low or undetectable concentrations of either unchanged material or the metabolite. Results from a bioavailability study established that plasma concentrations of loteprednol etabonate following ocular administration of one drop in each eye of Lotemax eight times daily for 2 days or four times daily for 42 days were below the limit of quantitation (1 ng/mL) and detection (500 pg/mL) at all sampling times. In the same study, plasma cortisol concentrations were measured and no evidence of adrenal cortex suppression was observed. All cortisol measurements were within normal range. This study suggests that limited, if any, systemic absorption occurs with Lotemax.